Skip to search formSkip to main contentSkip to account menu
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
TLDR
Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
View on PubMed
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
View on PubMed
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
TLDR
The recommended dose for disease-directed studies of OSI-774 administered orally on a daily, continuous, uninterrupted schedule is 150 mg/d, and several patients with epidermoid malignancies demonstrated either antitumor activity or relatively long periods of stable disease.
View on PubMed
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
TLDR
Objective antitumor activity and antiangiogenic effects were observed over a wide range of dose levels, suggesting that ramucirumab may have a favorable therapeutic index in treating malignancies amenable to VEGFR-2 inhibition.
View on PubMed
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
TLDR
Erlotinib was active and well tolerated in this patient population, and further clinical development is clearly warranted; cutaneous rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies.
View on PubMed
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
TLDR
Sorafenib has significant disease-stabilizing activity in metastatic renal cell carcinoma and is tolerable with chronic daily therapy.
View on PubMed
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
TLDR
Cetuximab is active and well tolerated in metastatic CRC refractory to irinotecan, oxaliplatin, and fluoropyrimidines and neither EGFR kinase domain mutations nor EGFR gene amplification appear to be essential for response to cetUXimab in this setting.
View on PubMed
Clinical toxicities encountered with paclitaxel (Taxol).
Although paclitaxel (TAXOL) appears to be one of the most promising antineoplastic agents of the last decade, with demonstrated activity in advanced and refractory ovarian, breast, lung, and head and…
View on PubMed
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
TLDR
Dxorubicin and paclitaxel, in the doses used here, have equivalent activity and the combination of AT results in superior overall response rates and time to TTF; and despite these results, combination therapy with AT did not improve either survival or quality of life compared to sequential single-agent therapy.
View on PubMed
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
TLDR
P protracted administration of temozolomide, even at relatively low daily doses, leads to significant and prolonged depletion of AGAT activity, which may enhance the antitumour activity of the agent.
View on Springer
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License